This investigation compound was 1st described by Hoffman-La Roche in 2009. It’s considered one of several benzodiazepines in the imidazobenzodiazepine subgroup assumed to offer nootropic Rewards.Diazepam is often viewed as the benchmark for evaluating the potency of other benzodiazepines. Potencies are usually assessed because of the equal dose i… Read More